|
FKRP expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.50759999992556E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.51910000321254E-08 |
| Normal-vs-Stage2 |
1.764820E-04 |
| Normal-vs-Stage3 |
5.40529998538375E-09 |
| Normal-vs-Stage4 |
1.18360000023188E-07 |
| Stage1-vs-Stage2 |
7.705800E-01 |
| Stage1-vs-Stage3 |
3.346300E-02 |
| Stage1-vs-Stage4 |
4.415800E-02 |
| Stage2-vs-Stage3 |
2.590600E-01 |
| Stage2-vs-Stage4 |
2.711000E-01 |
| Stage3-vs-Stage4 |
9.588800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.85589996096292E-09 |
| Normal-vs-AfricanAmerican |
5.189700E-04 |
| Normal-vs-Asian |
2.216500E-04 |
| Caucasian-vs-AfricanAmerican |
8.402800E-01 |
| Caucasian-vs-Asian |
2.108000E-01 |
| AfricanAmerican-vs-Asian |
3.209400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.51119999847182E-08 |
| Normal-vs-Female |
1.10340000003539E-06 |
| Male-vs-Female |
2.582600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.74417999999621E-05 |
| Normal-vs-Age(41-60Yrs) |
2.05010000087213E-08 |
| Normal-vs-Age(61-80Yrs) |
1.87080000380035E-08 |
| Normal-vs-Age(81-100Yrs) |
7.565800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.522800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.992100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.121400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.273600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.689200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.730800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.656410E-03 |
| Classical-VS-Follicular |
1.433390E-01 |
| Classical-VS-Other |
5.641400E-01 |
| Classical-VS-Normal |
1.94610999999512E-05 |
| Tall-VS-Follicular |
5.519500E-02 |
| Tall-VS-Other |
2.593800E-01 |
| Tall-VS-Normal |
6.85629997221326E-09 |
| Follicular-VS-Other |
9.954600E-01 |
| Follicular-VS-Normal |
1.03129999995399E-06 |
| Other-VS-Normal |
2.707900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
3.39260000092878E-08 |
| Normal-vs-N1 |
2.33159999999399E-05 |
| N0-vs-N1 |
9.574600E-01 |
|
|
